| Powder: -20°C for 3 years | In solvent: -80°C for 2 years
Equol 是雌激素受体β的高亲和力配体。
产品描述 | S-equol is an orally bioavailable, non-steroidal estrogen naturally produced by the metabolism of the isoflavonoid daidzein by human intestinal microflora, with potential chemoprotective and estrogen receptor (ER) modulating activities. S-equol preferentially binds to and activates the beta isoform of ER in certain target tissues, while having an antagonistic effect in other tissues. This modulates the expression of ER-responsive genes in a tissue-specific manner. This agent may increase bone mineral density, affect vasomotor symptoms, and may decrease the proliferation rate of susceptible cancer cells. In addition, this agent interferes with the activity of enzymes involved in steroid biosynthesis. S-equol inhibits dihydrotestosterone (DHT) production and may inhibit the proliferation of androgen-driven prostate cancer. S-equol is the biologically active enantiomer while R-equol is essentially inactive and has a weak affinity for alpha-ER. |
靶点活性 | estrogen receptor β:0.73 nM(Ki) |
体外活性 | Equol is a metabolite produced from the soy phytoestrogen daidzein by the action of gut microflora. Equol has higher affinity for both ERs (estrogen receptors including ERalpha and ERbeta). Equol exists as the enantiomers R-equol and S-equol. S-equol has a high binding affinity, preferential for ERbeta with a Ki of 16 nM whereas R-equol binds more weakly and with a preference for ERalpha K with a Ki of 50 nM. [1] Equol is superior to all other isoflavones in its antioxidant activity. [2] Equol has antioestrogenic properties. [3] Equol is a 100-fold more potent than daidzein in stimulating an oestrogenic response. Equol is also more effective than daidzein in competing with 3 H-oestradiol for binding to the ER. Equol stimulates the growth of MCF-7 cells in a concentration-dependent manner. Although equol exhibits oestrogenic activity, exposure of MCF-7 cells to equol simultaneously with oestradiol is effective in reducing pS2 mRNA expression. Equol results in the downregulation of ER mRNA expression. [4] |
细胞实验 | Each well of a 24-well plate is seeded with 1 × 105 MCF-7 cells in 1 mL of media B. Twenty-four hours after plating, equol at the indicated concentration is added. Equol is dissolved in ethanol (final concentration of ethanol in the medium is 1%). The medium is changed every 24 hours and equol is replenished with each change. Cell growth is determined on the sixth day by the sulphorhodamine colorimetric assay. After colour development, aliquots are pipetted into a 96-well microtitre plate and the absorbance is determined at 570 nm using an Elisa microplate reader.(Only for Reference) |
别名 | 4',7-Dihydroxyisoflavan, Equol, 雌马酚, 4',7-Isoflavandiol, (−)-Equol |
分子量 | 242.27 |
分子式 | C15H14O3 |
CAS No. | 531-95-3 |
| Powder: -20°C for 3 years | In solvent: -80°C for 2 years
DMSO: 24.2 mg/mL (100 mM)
Ethanol: 24.2 mg/mL (100 mM)
( < 1 mg/mL refers to the product slightly soluble or insoluble )
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
bottom
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
(-)-(S)-Equol 531-95-3 Endocrinology/Hormones Metabolism Estrogen/progestogen Receptor Estrogen Receptor/ERR Endogenous Metabolite Inhibitor inhibit 4',7-Dihydroxyisoflavan Equol ( ) (S) Equol 雌马酚 ()(S)Equol 4',7-Isoflavandiol (−)-Equol inhibitor